Aktienanalyse zu InspireMD Inc (NSPR)NSPRInspireMD Inc

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

InspireMD Inc is currently priced at $0.85, which is significantly below the analyst price targets of $3 and $4, indicating potential upside. However, the company has faced a 54.30% decline year-to-date and a 65.02% drop over the past year, reflecting ongoing challenges. The RSI is at 42.205, suggesting it is neither overbought nor oversold, which supports a hold position rather than a buy. The main risk is the company's recent product recall and the withdrawal of 2026 revenue guidance, which could impact future performance.